Alliance Pharma PLC Notification of Preliminary Results (2761Y)
March 02 2017 - 2:01AM
UK Regulatory
TIDMAPH
RNS Number : 2761Y
Alliance Pharma PLC
02 March 2017
For immediate release 2 March 2017
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Notification of Preliminary Results
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical
company, will announce its preliminary results for the year ended
31 December 2016 on Wednesday 29 March 2017.
A briefing for analysts will be held at 10.00am on the morning
of the results at the offices of Buchanan, 107 Cheapside, London
EC2V 6DN.
For more information please contact Buchanan on 020 7466
5000.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Andrew Franklin, Chief Financial
Officer
www.alliancepharma.co.uk
+ 44 (0) 20 7466
Buchanan 5000
Mark Court / Sophie Cowles
/ Jane Glover
+ 44 (0) 20 7260
Numis Securities Limited 1000
Nominated Adviser: Michael
Meade / Freddie Barnfield
Corporate Broking: James
Black / Toby Adcock
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has sales in more than 100 countries worldwide via direct
sales, joint ventures and a network of distributors. Alliance has a
strong track record of acquiring the rights to established niche
products and it currently owns or licenses the rights to
approximately 90 pharmaceutical and consumer healthcare products.
The Company continues to explore opportunities to expand its
product portfolio.
Alliance joined the AIM market of the London Stock Exchange in
December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORLLFVRVDILIID
(END) Dow Jones Newswires
March 02, 2017 02:01 ET (07:01 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Sep 2023 to Sep 2024